Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
FGFR inhibitor (specialist)

Pemigatinib

Brand names: Pemazyre

Pemigatinib is an oral fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor used principally in cholangiocarcinoma harbouring an FGFR2 fusion or rearrangement.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits FGFR1-3 kinase activity, blocking aberrant downstream signalling that drives proliferation in FGFR-altered tumours.

Prescribing in practice

  • Hyperphosphataemia is an expected on-target effect and can lead to soft-tissue mineralisation, so serum phosphate must be monitored and managed with diet, phosphate binders, and dose modification per the SPC.
  • Use is restricted to patients with a confirmed FGFR2 fusion/rearrangement identified by validated testing.
  • Serous retinal detachment and other retinal pigment epithelial changes can occur, warranting baseline and periodic ophthalmological assessment.

Monitoring

Monitor serum phosphate and calcium, retinal function via ophthalmological examination, and full blood count alongside routine biochemistry.

Counselling the patient

  • Attend all eye examinations and report any new visual symptoms such as blurring or floaters promptly.
  • Follow advice on diet and any prescribed phosphate-lowering measures.
  • This medicine can harm an unborn baby; use effective contraception as advised.

Evidence & guidelines

Approval was supported by the FIGHT-202 study in previously treated FGFR2-fusion cholangiocarcinoma.

Reference: NICE TA722 / TA929; ESMO biliary tract cancer guidelines; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways